New Advocacy Group Is Sponsoring Lung Cancer Awareness Day

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

VANCOUVER, Wa--Lung cancer is the leading cause of cancer-related deaths in the United States, yet there are no colored ribbons for survivors and supporters, no races for a cure, and until now, no day, week, or month dedicated to lung cancer awareness.

VANCOUVER, Wa--Lung cancer is the leading cause of cancer-related deathsin the United States, yet there are no colored ribbons for survivors andsupporters, no races for a cure, and until now, no day, week, or monthdedicated to lung cancer awareness.

The Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE)is changing this, designating November 14, 1997, as the first Lung CancerAwareness Day, to remember those who have lost their lives to lung cancerand to show support for those living with the disease.

ALCASE, the only national nonprofit organization dedicated solely tohelping people with lung cancer, is also distributing clear plastic "invisible"ribbons to represent the hundreds of thousands of Americans who are partof the "invisible" population affected by lung cancer.

The organization provides free of charge the quarterly newsletter, Spiritand Breath; Phone Buddies, a peer-to-peer support program; customizedinformation searches; phone support groups; and resources and referrals.Telephone support is available at 1-800-298-2436; online help is availableon ALCASE's web page (http://www.teleport.com/~alcase).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content